Biotech | March 10, 2022
Gufic Biosciences collaborates with Selvax for cancer treatment
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th 2021
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Sense anticipates launching Veros Covid-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Subscribe To Our Newsletter & Stay Updated
